XPH holdings
All 62 positions of State Street SPDR S&P Pharmaceuticals ETF.
Positions
62
Top 10 weight
22.7%
Effective holdings
55.6
1 / sum of squared weights
In stocks
99.9%
In bonds
0.0%
Outside the US
0.0%
Asset mix
Sectors
100% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | XERSXeris Biopharma Holdings, Inc. Common Stock | Equity | 2.69% | — | 1,216,429 | US |
| 2 | MANEVeradermics, Incorporated | Equity | 2.58% | — | 94,103 | US |
| 3 | PCRXPacira BioSciences, Inc. Common Stock | Equity | 2.58% | — | 326,869 | US |
| 4 | AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock | Equity | 2.31% | — | 543,693 | US |
| 5 | VTRSViatris Inc. Common Stock | Equity | 2.15% | — | 568,404 | US |
| 6 | LLYEli Lilly & Co. | Equity | 2.11% | — | 8,334 | US |
| 7 | CORTCorcept Therapeutics Inc. | Equity | 2.08% | — | 81,067 | US |
| 8 | LGNDLigand Pharmaceuticals Inc. | Equity | 2.08% | — | 32,552 | US |
| 9 | INDVIndivior Pharmaceuticals, Inc. Common Stock | Equity | 2.07% | — | 269,738 | US |
| 10 | ANIPANI Pharmaceuticals, Inc. | Equity | 2.07% | — | 132,661 | US |
| 11 | PRGOPERRIGO COMPANY PLC | Equity | 2.05% | — | 654,017 | |
| 12 | OGNOrganon & Co. | Equity | 2.04% | — | 686,070 | US |
| 13 | SUPNSupernus Pharmaceuticals, Inc. | Equity | 2.04% | — | 222,935 | US |
| 14 | PFEPfizer Inc. | Equity | 2.03% | — | 337,607 | US |
| 15 | ZTSZOETIS INC. | Equity | 2.03% | — | 127,926 | US |
| 16 | INVAInnoviva, Inc. Common Stock | Equity | 2.01% | — | 443,858 | US |
| 17 | OMEROmeros Corporation | Equity | 2.00% | — | 483,687 | US |
| 18 | PBHPrestige Consumer Healthcare Inc. | Equity | 2.00% | — | 192,577 | US |
| 19 | MRKMerck & Co., Inc. | Equity | 1.96% | — | 63,564 | US |
| 20 | JNJJohnson & Johnson | Equity | 1.95% | — | 35,122 | US |
| 21 | ELANElanco Animal Health Incorporated Common Stock | Equity | 1.94% | — | 398,243 | US |
| 22 | HRMYHarmony Biosciences Holdings, Inc. Common Stock | Equity | 1.93% | — | 225,338 | US |
| 23 | MAZEMaze Therapeutics, Inc. Common Stock | Equity | 1.90% | — | 339,493 | US |
| 24 | ETONEton Pharmaceutcials, Inc. Common Stock | Equity | 1.89% | — | 159,420 | US |
| 25 | RPRXRoyalty Pharma plc Class A Ordinary Shares | Equity | 1.89% | — | 154,790 | |
| 26 | BMYBristol-Myers Squibb Co. | Equity | 1.88% | — | 145,603 | US |
| 27 | COLLCollegium Pharmaceutical, Inc. Common Stock | Equity | 1.88% | — | 392,104 | US |
| 28 | JAZZJazz Pharmaceuticals, Inc. | Equity | 1.87% | — | 38,869 | |
| 29 | SEPNSepterna, Inc. Common Stock | Equity | 1.85% | — | 231,022 | US |
| 30 | EWTXEdgewise Therapeutics, Inc. Common Stock | Equity | 1.84% | — | 216,149 | US |
| 31 | DFTXDefinium Therapeutics, Inc. Common Shares | Equity | 1.83% | — | 246,872 | |
| 32 | TARSTarsus Pharmaceuticals, Inc. Common Stock | Equity | 1.77% | — | 113,307 | US |
| 33 | MBXMBX Biosciences, Inc. Common Stock | Equity | 1.72% | — | 149,074 | US |
| 34 | AMLXAmylyx Pharmaceuticals, Inc. Common Stock | Equity | 1.71% | — | 289,463 | US |
| 35 | HROWHarrow, Inc. Common Stock | Equity | 1.65% | — | 249,764 | US |
| 36 | AXSMAxsome Therapeutics, Inc | Equity | 1.64% | — | 44,531 | US |
| 37 | AMPHAmphastar Pharmaceuticals, Inc. | Equity | 1.58% | — | 282,519 | US |
| 38 | ZVRAZevra Therapeutics, Inc. Common Stock | Equity | 1.58% | — | 661,975 | US |
| 39 | TRVITrevi Therapeutics, Inc. Common Stock | Equity | 1.57% | — | 563,622 | US |
| 40 | NUVBNuvation Bio Inc. | Equity | 1.54% | — | 1,438,438 | US |
| 41 | ALMSAlumis Inc. Common Stock | Equity | 1.45% | — | 957,006 | US |
| 42 | ELVNEnliven Therapeutics, Inc. Common Stock | Equity | 1.44% | — | 163,250 | US |
| 43 | OCULOcular Therapeutix, Inc. | Equity | 1.33% | — | 817,660 | US |
| 44 | WVEWave Life Sciences Ltd. Ordinary Shares | Equity | 1.31% | — | 1,744,065 | |
| 45 | RAPPRapport Therapeutics, Inc. Common Stock | Equity | 1.28% | — | 198,550 | US |
| 46 | LBRXLB Pharmaceuticals Inc Common Stock | Equity | 1.27% | — | 169,555 | US |
| 47 | PAHCPhibro Animal Health Corporation Class A | Equity | 1.25% | — | 154,425 | US |
| 48 | CRMDCorMedix Inc. | Equity | 1.22% | — | 769,525 | US |
| 49 | AQSTAquestive Therapeutics, Inc. Common Stock | Equity | 1.22% | — | 1,182,601 | US |
| 50 | ANROAlto Neuroscience Inc. | Equity | 1.18% | — | 227,540 | US |
| 51 | PHATPhathom Pharmaceuticals, Inc. Common Stock | Equity | 1.14% | — | 735,039 | US |
| 52 | ACRSAclaris Therapeutics, Inc. | Equity | 0.85% | — | 1,032,703 | US |
| 53 | LQDALiquidia Corporation Common Stock | Equity | 0.82% | — | 135,692 | US |
| 54 | RLMDRelmada Therapeutics, Inc. Common Stock | Equity | 0.81% | — | 1,182,971 | US |
| 55 | AVLNAvalyn Pharma Inc. Common Stock | Equity | 0.79% | — | 140,931 | US |
| 56 | LXRXLexicon Pharmaceuticals, Inc. | Equity | 0.78% | — | 2,052,156 | US |
| 57 | EYPTEyePoint, Inc. Common Stock | Equity | 0.77% | — | 1,021,925 | US |
| 58 | ARVNArvinas, Inc | Equity | 0.74% | — | 457,705 | US |
| 59 | EOLSEvolus, Inc. Common Stock | Equity | 0.72% | — | 424,725 | US |
| 60 | CTNMContineum Therapeutics, Inc. Class A Common Stock | Equity | 0.65% | — | 227,797 | US |
| 61 | BIOABioAge Labs, Inc. Common Stock | Equity | 0.62% | — | 462,042 | US |
| 62 | SSI US GOV MONEY MARKET CLASS | Cash | 0.07% | — | 329,117 |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| Exit | TERNTerns Pharmaceuticals Inc | 2.16% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | ATAIAtaiBeckley Inc | — | 2.13% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | MANEVeraDermics Inc | — | 2.02% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | ETONEton Pharmaceuticals Inc | — | 1.30% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | DFTXDefinium Therapeutics Inc | 1.95% | 3.09% | −17.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | RLMDRelmada Therapeutics Inc | — | 1.06% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | ACRSAclaris Therapeutics Inc | — | 0.89% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | MAZEMaze Therapeutics Inc | 1.13% | 1.85% | +110.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ANROAlto Neuroscience Inc | 0.54% | 1.17% | +140.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | LXRXLexicon Pharmaceuticals Inc | — | 0.63% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | CORTCorcept Therapeutics Inc | 2.29% | 1.70% | −55.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | WaVe Life Sciences Ltd | 0.99% | 1.57% | +155.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ZTSZoetis Inc | 1.89% | 1.35% | +51.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ALMSAlumis Inc | 1.60% | 2.14% | +34.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | EOLSEvolus Inc | — | 0.53% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | AXSMAxsome Therapeutics Inc | 2.03% | 1.52% | −33.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | PAHCPhibro Animal Health Corp | 1.79% | 1.28% | +62.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Theravance Biopharma Inc | 1.42% | 0.96% | −16.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | XERSXeris Biopharma Holdings Inc | 1.84% | 1.39% | −28.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | ESPREsperion Therapeutics Inc | 1.95% | 1.54% | −12.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Royalty Pharma PLC | 1.97% | 1.57% | −12.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | BMYBristol-Myers Squibb Co | 1.94% | 1.58% | +10.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | TARSTarsus Pharmaceuticals Inc | 1.93% | 1.57% | +17.0% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | ELVNEnliven Therapeutics Inc | 2.45% | 2.09% | −14.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Jazz Pharmaceuticals PLC | 1.96% | 1.60% | −17.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | BIOABioAge Labs Inc | 1.20% | 1.50% | +15.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | HRMYHarmony Biosciences Holdings Inc | 1.87% | 1.57% | −16.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | SUPNSupernus Pharmaceuticals Inc | 1.86% | 1.57% | +21.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | PBHPrestige Consumer Healthcare Inc | 1.75% | 1.47% | +35.3% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | OMEROmeros Corp | 1.70% | 1.42% | +20.0% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | AMLXAmylyx Pharmaceuticals Inc | 1.79% | 2.04% | +13.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | CRNXCrinetics Pharmaceuticals Inc | 1.88% | 1.66% | +10.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | AMRXAmneal Pharmaceuticals Inc | 1.88% | 1.72% | −14.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | INDVIndivior Pharmaceuticals Inc | 1.78% | 1.64% | −11.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | EYPTEyePoint Inc | 1.66% | 1.77% | +24.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | AQSTAquestive Therapeutics Inc | 0.81% | 0.76% | +21.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | LQDALiquidia Corp | 1.88% | 1.86% | −39.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | NKTRNektar Therapeutics | 1.88% | 1.88% | +32.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | OCULOcular Therapeutix Inc | 1.71% | 1.71% | +11.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ARVNArvinas Inc | 1.25% | 1.25% | +64.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | Indivior PLC | 1.89% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | Avadel Pharmaceuticals PLC | 1.87% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | INDVIndivior Pharmaceuticals Inc | — | 1.78% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | CORTCorcept Therapeutics Inc | 0.76% | 2.29% | +163.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | ELVNEnliven Therapeutics Inc | 1.08% | 2.45% | −10.1% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | ALMSAlumis Inc | 0.32% | 1.60% | +124.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | BIOABioAge Labs Inc | — | 1.20% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | VTYXVentyx Biosciences Inc | 0.98% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | LENZLENZ Therapeutics Inc | 0.96% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | EOLSEvolus Inc | 0.96% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | FULCFulcrum Therapeutics Inc | — | 0.92% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | LBRXLB Pharmaceuticals Inc | — | 0.71% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | WaVe Life Sciences Ltd | 1.57% | 0.99% | +49.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | Theravance Biopharma Inc | 0.85% | 1.42% | +94.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | ANROAlto Neuroscience Inc | — | 0.54% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | RAPPRapport Therapeutics Inc | 1.89% | 1.37% | −28.9% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | NKTRNektar Therapeutics | 1.36% | 1.88% | −18.0% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | CRMDCorMedix Inc | 1.65% | 1.22% | +28.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | ARVNArvinas Inc | 1.67% | 1.25% | −15.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | PHATPhathom Pharmaceuticals Inc | 1.83% | 1.44% | +18.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.